There were 556 press releases posted in the last 24 hours and 438,107 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image